Where Will Cara Therapeutics Inc (CARA) Stock Go Next After It Has Fallen 9.89% in a Week?

The market has been neutral on Cara Therapeutics Inc (CARA) stock recently. CARA gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Cara Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on CARA!

See Full CARA Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CARA Stock Today?

Cara Therapeutics Inc (CARA) stock is trading at $0.82 as of 11:13 AM on Monday, Mar 25, a loss of -$0.06, or -7.22% from the previous closing price of $0.88. The stock has traded between $0.81 and $0.92 so far today. Volume today is low. So far 136,753 shares have traded compared to average volume of 880,456 shares.

More About Cara Therapeutics Inc

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features. Click Here to get the full Stock Report for Cara Therapeutics Inc stock.